35. RISK FACTORS FOR PROGRESSION OF DIABETIC RETINOPATHY IN PATIENTS WITH TYPE 1 DIABETES
Main Article Content
Abstract
Objectives: Evaluation of risk factors for progression of diabetic retinopathy (DR) in patients with insulin-dependent diabetes mellitus (type 1 diabetes).
Subjects and methods: Descriptive study on 154 patients with insulin-dependent diabetes who were scheduled for eye examination from January 2023 to February 2024 at Nghe An General Friendship Hospital and Nghe An Eye Hospital.
Results: There is a relationship between age of type 1 diabetes and stages of diabetic retinopathy. The younger the age of type 1 diabetes, the higher the risk of proliferative diabetic retinopathy (p<0.01. The higher the HbA1C concentration, the higher the risk of progression to proliferative diabetic retinopathy, the difference being high in the group with HbA1c >9.9 (OR: 24.8; CI 3.7-215.5). There is also a threshold effect of diastolic blood pressure. That is, when diastolic blood pressure exceeds the threshold of 80 mmHg, the risk of developing proliferative diabetic retinopathy does not increase. Body mass index of patients with type 1 diabetes; Diastolic blood pressure; Duration of type 1 diabetes and fasting blood sugar levels have not shown any differences between groups of patients at different stages of diabetic retinopathy.
Article Details
Keywords
Non-insulin-dependent diabetes mellitus (type 1 diabetes), diabetic retinopathy, proliferative diabetic retinopathy
References
[2]. T.-E. Tan and T. Y. Wong, “Diabetic retinopathy: Looking forward to 2030,” Front. Endocrinol, vol. 13, Jan. 2023, doi: 10.3389/fendo.2022.1077669.
[3]. Rahul Deb Bera, Subhra Chandra Chandra, “Assessment of Macular Thickness and Retinal Nerve Fiber Layer Thickness by Spectral Domain OCT in Patients with Type 2 Diabetes Mellitus Without Clinical Diabetic Retinopathy in Relation about the Glycemic Status and Oxidized Low Density Lipoprotein levels,” Int. J. Med. Sci. Curr. Res. IJMSCR, vol. 7, no. 1, 2024.
[4]. Diabetic retinopathy screening: a short guide: increase effectiveness, maximize benefits and minimize harm. Accessed: Sep. 26, 2024. [Online]. Available:https://www.who.int/europe/
publications/i/item/9789289055321
[5]. Thắng T. T., Huỳnh N. S., and Dung N. T., “phân tích các giai đoạn của bệnh lý võng mạc đái tháo đường dựa trên hình chụp ảnh màu đáy mắt của người bệnh đái tháo đường trong cộng đồng tại Nghệ An,” Tạp Chí Y Học Việt Nam, vol. 537, no. 1, Art. no. 1, Apr. 2024, doi: 10.51298/vmj.v537i1.9058.
[6]. S. Vujosevic et al., “Screening for diabetic retinopathy: new perspectives and challenges” Lancet Diabetes Endocrinol., vol.8, no.4, pp.337–347, Apr.2020, doi:10.1016/S2213-8587(19) 30411-5.
[7]. P. Romero-Aroca, R. Navarro-Gil, A. Valls-Mateu, R. Sagarra-Alamo, A. Moreno-Ribas, and N. Soler, “Differences in incidence of diabetic retinopathy between type 1 and 2 diabetes mellitus: a nine-year follow-up study,” Br. J. Ophthalmol., vol.101, no.10, pp.1346–1351, Oct.2017, doi: 10.1136/bjophthalmol-2016-310063.
[8]. P. Alvarez-Ramos, S. Jimenez-Carmona, P. Alemany-Marquez, J. A. Cordoba-Doña, and M. Aguilar-Diosdado, “Socioeconomic deprivation and development of diabetic retinopathy in patients with type 1 diabetes mellitus” BMJ Open Diabetes Res. Care, vol. 8, no. 2, p. e001387, Nov. 2020, doi: 10.1136/bmjdrc-2020-001387.
[9]. T. Um, E. J. Seo, Y. J. Kim, and Y. H. Yoon, “Optical coherence tomography angiography findings of type 1 diabetic patients with diabetic retinopathy, in comparison with type 2 patients” Graefes Arch. Clin. Exp. Ophthalmol., vol. 258, no. 2, pp. 281–288, Feb. 2020, doi: 10.1007/s00417-019-04517-6.